Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083
Todd T. Brown(Johns Hopkins University), Raphael J. Landovitz(APLA Health), Beatriz Grinsztejn(Fundação Oswaldo Cruz), Marybeth McCauley(Family Health International 360), James F. Rooney(Gilead Sciences (United States)), Nittaya Phanuphak(HIV Netherlands Australia Thailand Research Collaboration), Temitope Oyedele(AstraZeneca (South Korea)), Philip A. Sullivan(Johns Hopkins University), Brett Hanscom(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Alex R. Rinehart, Maryam Warsi(Fred Hutch Cancer Center), Robert F. Arao(Fred Hutch Cancer Center), Ricardo Vasconcelos(Universidade de São Paulo)
Cited by 2
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
|New England Journal of Medicine|2015|1.6k
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|891